Foghorn Therapeutics (FHTX) Research & Development (2019 - 2026)

Foghorn Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• On a quarterly basis, Research & Development fell 15.57% year-over-year to $18.3 million in Q1 2026; TTM through Mar 2026 was $82.1 million, a 9.4% decrease from a year earlier, with the FY2025 full-year figure at $85.5 million, down 9.59% from the prior year.
• Research & Development slipped to $18.3 million in Q1 2026 per FHTX's latest filing, from $22.0 million in the prior quarter.
• Across five years, Research & Development topped out at $30.0 million in Q1 2023 and bottomed at $18.3 million in Q1 2026.
• The 5-year median for Research & Development is $24.5 million (2022), against an average of $24.3 million.
• Across the five-year window, Research & Development jumped 39.33% in 2022 and declined 18.98% in 2025, its largest moves.
• Year by year, Research & Development stood at $28.2 million in 2022, then decreased by 14.19% to $24.2 million in 2023, then slipped by 15.27% to $20.5 million in 2024, then increased by 7.5% to $22.0 million in 2025, then fell by 17.18% to $18.3 million in 2026.
• Per Business Quant, the three latest FHTX Research & Development figures stand at $18.3 million (Q1 2026), $22.0 million (Q4 2025), and $20.0 million (Q3 2025).